Viking Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Viking Therapeutics Inc 's ROA in the third quarter of 2026?
Viking Therapeutics Inc recorded a cumulative net loss of $-627 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -88.87%.

However, within the Healthcare sector 715 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4109, from total ROA ranking in the second quarter of 2026 at 4570.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	32.15 %	-36.96 %	-29.84 %	-21.2 %	-21.15 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-627	-535	-472	-360	-237
Return On Assets (TTM)	-88.87 %	-82.74 %	-65.35 %	-45.67 %	-28.41 %
VKTX's Total Ranking	# 4109	# 4570	# 3750	# 3589	# 3485
Total Assets (TTM) in million	977	522	608	716	739
Seq. Total Assets Change	87.23 %	-14.2 %	-15.02 %	-3.2 %	-10.68 %
Seq. Net Income Change	-	-	-	-	-

VKTX's 5 Years Annual ROA >> Back to VKTX Management Effectiveness >> Compare VKTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 328
Sector	# 716
Overall	# 4199

Return On Assets Statistics
High	Average	Low
-7.94 %	-45.87 %	-157.36 %
(Sep 30 2019)		(Dec 31 2015)

Financial Statements
Viking Therapeutics Inc 's Assets	$ 977 million	VKTX's Balance sheet
Viking Therapeutics Inc 's Income	$ -183 million	Quarterly VKTX's Income Statement
VKTX's Income by Division		See VKTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-21.2 %	146.64 %	119.11 %	-20.22 %	-17.87 %
Total Assets in million	716	908	368	168	211
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-360	-110	-86	-69	-55
Annual Return On Assets	-50.25 %	-12.11 %	-23.32 %	-40.97 %	-26.1 %

VKTX's 5 Years Annual ROA >> Back to VKTX Management Effectiveness >> Compare VKTX ROA to its Competitors

More Return On Assets Ratios
VKTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VKTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VKTX's Competitors
Subscribers only: Roa for Viking Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for VKTX's Customers

You may also want to know
VKTX's Roi	VKTX's Inventory Turnover Ratio	VKTX's Growth Rates	VKTX's Dividend Comparisons
	VKTX's Profitability Ratios	VKTX's Asset Turnover Ratio	VKTX's Dividend Growth
VKTX's Roe	VKTX's Valuation Ratios	VKTX's Financial Strength Ratios	VKTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-10-30T13:26:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.